Loading clinical trials...
Loading clinical trials...
A Phase II Study Assessing Safety and Efficacy of REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis (REPOSE Study)
Conditions
Interventions
Repotrectinib
Locations
16
Austria
Medizinische Universität Graz
Graz, Austria
Medical University of Vienna
Vienna, Austria
Ludwig-Maximilians-University Munich
München, Germany
Hospital de Vinalopó
Elche, Alicante, Spain
Hospital Universitari Sant Joan de Reus
Reus, Tarragona, Spain
Hospital General Universitario Dr. Balmis
Alicante, Spain
Start Date
June 27, 2025
Primary Completion Date
March 1, 2027
Completion Date
April 1, 2028
Last Updated
February 25, 2026
NCT07363252
NCT07462507
NCT06758401
NCT06476808
NCT07528066
NCT06253871
Lead Sponsor
MedSIR
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions